EQS Group-News: Zur Rose Group AG / Key word(s): Change in Forecast
Zur Rose Group increases its financial targets
- Successful acquisition strategy enables higher sales growth
- Further efficiency increase expected after completion of expanded logistics centre in Heerlen
- EBITDA margin target increased to 5 to 6 percent in 2022
- Confirmation of revenue and earnings expectations for 2018
Due to the successful acceleration of the strategy driven by the acquisitions of Eurapon, Vitalsana, apo-rot, Promofarma and medpex, the Zur Rose Group is raising its medium-term financial targets. For 2019, the Group is targeting sales of at least CHF 1.6 billion, representing growth of more than 30 percent compared to the expected sales for 2018. In the following years until 2022, the company anticipates annual organic growth rates at group level of well above 10 percent. Furthermore, economies of scale after the completion of the new logistics facility in Heerlen, purchasing synergies and the reduction of overheads are expected to sustainably increase the operating result. Based on this, the Group is raising its EBITDA margin target for 2022 to 5 to 6 percent (previous guidance: 4 to 5 percent) on the basis of increased sales. For 2018, management confirms the communicated sales and earnings expectations.
At the DocMorris site in Heerlen, where apo-rot's shipping activities were successfully integrated as planned at the beginning of November 2018, the Zur Rose Group is expanding its logistics infrastructure with the construction of a new building. This new facility, adjacent to the existing building, is expected to go into operation in the course of 2021. Zur Rose Group anticipates it will enable the entire German mail order business to be handled in Heerlen. The new logistics facility is expected to triple the site's shipping capacity to a volume of 30 million parcels per year.
Investors and analyst contact
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest online pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.
The Zur Rose Group is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 983 million in the 2017 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com
|Company:||Zur Rose Group AG|
|Phone:||+41 52 724 08 14|
|Listed:||SIX Swiss Exchange|
|End of News||EQS Group News Service|